Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · IEX Real-Time Price · USD
-0.19 (-1.45%)
At close: Apr 16, 2024, 4:00 PM
-1.23 (-9.56%)
Pre-market: Apr 17, 2024, 5:33 AM EDT

Company Description

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States.

The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.

In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency.

The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products.

Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Precision BioSciences, Inc.
Precision BioSciences logo
Country United States
Founded 2006
IPO Date Mar 28, 2019
Industry Biotechnology
Sector Healthcare
Employees 109
CEO Michael Amoroso

Contact Details

302 East Pettigrew Street, Suite A-100
Durham, North Carolina 27701
United States
Phone 919-314-5512

Stock Details

Ticker Symbol DTIL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001357874
CUSIP Number 74019P108
ISIN Number US74019P2074
SIC Code 2836

Key Executives

Name Position
Michael Amoroso President, Chief Executive Officer and Director
John Alexander Kelly R.Ph. Chief Financial Officer and Principal Accounting Officer
Dario Scimeca General Counsel and Secretary
Dr. Jefferson J. Smith Ph.D. Co-Founder and Chief Research Officer
Mei Burris Director of Investor Relations and Finance
Bruce Stevens Vice President of Quality and Compliance
Maurissa Messier Senior Director of Corporate Communications
Juli Blanche Chief People Officer
Garrett Gincley Head of Manufacturing
Dr. Alan F. List M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Apr 16, 2024 8-K Current Report
Mar 27, 2024 10-K Annual Report
Mar 27, 2024 8-K Current Report
Mar 18, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Mar 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Mar 11, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Mar 4, 2024 424B5 Filing
Mar 1, 2024 8-K Current Report
Mar 1, 2024 FWP Free Writing Prospectus
Feb 29, 2024 424B5 Filing